Online inquiry

IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ8885MR)

This product GTTS-WQ8885MR is a type of mRNA modified with Pseudo-UTP, which ecodes the monoclonal antibody that targets IFNA1; IFNB1 gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_024013.3; NM_002176.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3439; 3456
UniProt ID P01562; P01574
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ8885MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13282MR IVTScrip™ mRNA-Anti-MSTN, PF-06252616(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-06252616
GTTS-WQ15462MR IVTScrip™ mRNA-Anti-ERBB3, U3-1287(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA U3-1287
GTTS-WQ8368MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ7100MR IVTScrip™ mRNA-Anti-IL6&IL6R, FE 999301(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FE 999301
GTTS-WQ2115MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ10582MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA LY-3127804
GTTS-WQ2249MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ALX-0171
GTTS-WQ3428MR IVTScrip™ mRNA-Anti-HGF, AV-299(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AV-299
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW